nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—TOP2A—Teniposide—lymphatic system cancer	0.285	0.352	CbGbCtD
Norfloxacin—TOP2A—Mitoxantrone—lymphatic system cancer	0.2	0.246	CbGbCtD
Norfloxacin—CYP1A2—Carmustine—lymphatic system cancer	0.0649	0.0802	CbGbCtD
Norfloxacin—CYP3A5—Teniposide—lymphatic system cancer	0.0586	0.0724	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0376	0.0465	CbGbCtD
Norfloxacin—CYP3A7—Vincristine—lymphatic system cancer	0.0376	0.0465	CbGbCtD
Norfloxacin—CYP3A5—Vincristine—lymphatic system cancer	0.0282	0.0348	CbGbCtD
Norfloxacin—SLC22A6—Methotrexate—lymphatic system cancer	0.025	0.0308	CbGbCtD
Norfloxacin—CYP3A4—Cytarabine—lymphatic system cancer	0.0232	0.0287	CbGbCtD
Norfloxacin—CYP3A4—Teniposide—lymphatic system cancer	0.0229	0.0282	CbGbCtD
Norfloxacin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.016	0.0197	CbGbCtD
Norfloxacin—CYP3A4—Vincristine—lymphatic system cancer	0.011	0.0136	CbGbCtD
Norfloxacin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.00123	0.195	CbGdCrCtD
Norfloxacin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.00094	0.149	CbGdCrCtD
Norfloxacin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.000887	0.14	CbGdCrCtD
Norfloxacin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	0.00056	0.0884	CbGdCrCtD
Norfloxacin—Rash—Mechlorethamine—lymphatic system cancer	0.000475	0.00259	CcSEcCtD
Norfloxacin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000475	0.00259	CcSEcCtD
Norfloxacin—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000472	0.00257	CcSEcCtD
Norfloxacin—Anorexia—Fludarabine—lymphatic system cancer	0.000466	0.00254	CcSEcCtD
Norfloxacin—Proteinuria—Methotrexate—lymphatic system cancer	0.000462	0.00252	CcSEcCtD
Norfloxacin—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000461	0.00251	CcSEcCtD
Norfloxacin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000459	0.0025	CcSEcCtD
Norfloxacin—Myocardial infarction—Vincristine—lymphatic system cancer	0.000459	0.0025	CcSEcCtD
Norfloxacin—Feeling abnormal—Teniposide—lymphatic system cancer	0.000458	0.00249	CcSEcCtD
Norfloxacin—Stomatitis—Vincristine—lymphatic system cancer	0.000456	0.00248	CcSEcCtD
Norfloxacin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000456	0.00248	CcSEcCtD
Norfloxacin—Protein urine present—Methotrexate—lymphatic system cancer	0.000456	0.00248	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000454	0.00247	CcSEcCtD
Norfloxacin—Chills—Bleomycin—lymphatic system cancer	0.000452	0.00246	CcSEcCtD
Norfloxacin—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000449	0.00245	CcSEcCtD
Norfloxacin—Renal failure—Mitoxantrone—lymphatic system cancer	0.000448	0.00244	CcSEcCtD
Norfloxacin—Nausea—Mechlorethamine—lymphatic system cancer	0.000448	0.00244	CcSEcCtD
Norfloxacin—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000447	0.00243	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000445	0.00242	CcSEcCtD
Norfloxacin—Jaundice—Mitoxantrone—lymphatic system cancer	0.000444	0.00242	CcSEcCtD
Norfloxacin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000444	0.00242	CcSEcCtD
Norfloxacin—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000443	0.00241	CcSEcCtD
Norfloxacin—Urticaria—Teniposide—lymphatic system cancer	0.000442	0.0024	CcSEcCtD
Norfloxacin—Body temperature increased—Teniposide—lymphatic system cancer	0.000439	0.00239	CcSEcCtD
Norfloxacin—Abdominal pain—Teniposide—lymphatic system cancer	0.000439	0.00239	CcSEcCtD
Norfloxacin—Erythema—Bleomycin—lymphatic system cancer	0.000439	0.00239	CcSEcCtD
Norfloxacin—Paraesthesia—Fludarabine—lymphatic system cancer	0.000439	0.00239	CcSEcCtD
Norfloxacin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000438	0.00238	CcSEcCtD
Norfloxacin—Hallucination—Carmustine—lymphatic system cancer	0.000438	0.00238	CcSEcCtD
Norfloxacin—Dyspnoea—Fludarabine—lymphatic system cancer	0.000435	0.00237	CcSEcCtD
Norfloxacin—Haematuria—Mitoxantrone—lymphatic system cancer	0.000434	0.00237	CcSEcCtD
Norfloxacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00043	0.00234	CcSEcCtD
Norfloxacin—Dysarthria—Methotrexate—lymphatic system cancer	0.000429	0.00234	CcSEcCtD
Norfloxacin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000425	0.00232	CcSEcCtD
Norfloxacin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000425	0.00231	CcSEcCtD
Norfloxacin—Visual impairment—Carmustine—lymphatic system cancer	0.000424	0.00231	CcSEcCtD
Norfloxacin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	0.000423	0.0669	CbGdCrCtD
Norfloxacin—Fatigue—Fludarabine—lymphatic system cancer	0.000421	0.00229	CcSEcCtD
Norfloxacin—Hallucination—Vincristine—lymphatic system cancer	0.000418	0.00228	CcSEcCtD
Norfloxacin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000418	0.00228	CcSEcCtD
Norfloxacin—Constipation—Fludarabine—lymphatic system cancer	0.000418	0.00227	CcSEcCtD
Norfloxacin—Vasculitis—Methotrexate—lymphatic system cancer	0.000416	0.00226	CcSEcCtD
Norfloxacin—Hypersensitivity—Teniposide—lymphatic system cancer	0.000409	0.00223	CcSEcCtD
Norfloxacin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000409	0.00223	CcSEcCtD
Norfloxacin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000403	0.00219	CcSEcCtD
Norfloxacin—Asthenia—Teniposide—lymphatic system cancer	0.000399	0.00217	CcSEcCtD
Norfloxacin—Pruritus—Teniposide—lymphatic system cancer	0.000393	0.00214	CcSEcCtD
Norfloxacin—Leukopenia—Bleomycin—lymphatic system cancer	0.000393	0.00214	CcSEcCtD
Norfloxacin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	0.000391	0.0618	CbGdCrCtD
Norfloxacin—Body temperature increased—Fludarabine—lymphatic system cancer	0.000386	0.0021	CcSEcCtD
Norfloxacin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	0.000385	0.0608	CbGdCrCtD
Norfloxacin—Erythema—Carmustine—lymphatic system cancer	0.000383	0.00209	CcSEcCtD
Norfloxacin—Diarrhoea—Teniposide—lymphatic system cancer	0.00038	0.00207	CcSEcCtD
Norfloxacin—Myalgia—Bleomycin—lymphatic system cancer	0.000374	0.00203	CcSEcCtD
Norfloxacin—Chest pain—Bleomycin—lymphatic system cancer	0.000374	0.00203	CcSEcCtD
Norfloxacin—Back pain—Carmustine—lymphatic system cancer	0.000371	0.00202	CcSEcCtD
Norfloxacin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	0.00037	0.0584	CbGdCrCtD
Norfloxacin—Chills—Mitoxantrone—lymphatic system cancer	0.000367	0.002	CcSEcCtD
Norfloxacin—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000367	0.002	CcSEcCtD
Norfloxacin—Confusional state—Bleomycin—lymphatic system cancer	0.000361	0.00197	CcSEcCtD
Norfloxacin—Vision blurred—Carmustine—lymphatic system cancer	0.000361	0.00197	CcSEcCtD
Norfloxacin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00036	0.00196	CcSEcCtD
Norfloxacin—Tremor—Carmustine—lymphatic system cancer	0.000359	0.00195	CcSEcCtD
Norfloxacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000358	0.00195	CcSEcCtD
Norfloxacin—Oedema—Bleomycin—lymphatic system cancer	0.000358	0.00195	CcSEcCtD
Norfloxacin—Erythema—Mitoxantrone—lymphatic system cancer	0.000356	0.00194	CcSEcCtD
Norfloxacin—Back pain—Vincristine—lymphatic system cancer	0.000354	0.00193	CcSEcCtD
Norfloxacin—Vomiting—Teniposide—lymphatic system cancer	0.000353	0.00192	CcSEcCtD
Norfloxacin—Agitation—Carmustine—lymphatic system cancer	0.000352	0.00192	CcSEcCtD
Norfloxacin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000351	0.00191	CcSEcCtD
Norfloxacin—Asthenia—Fludarabine—lymphatic system cancer	0.00035	0.00191	CcSEcCtD
Norfloxacin—Rash—Teniposide—lymphatic system cancer	0.00035	0.00191	CcSEcCtD
Norfloxacin—Dermatitis—Teniposide—lymphatic system cancer	0.00035	0.00191	CcSEcCtD
Norfloxacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000349	0.0019	CcSEcCtD
Norfloxacin—Headache—Teniposide—lymphatic system cancer	0.000348	0.0019	CcSEcCtD
Norfloxacin—Pruritus—Fludarabine—lymphatic system cancer	0.000346	0.00188	CcSEcCtD
Norfloxacin—Back pain—Mitoxantrone—lymphatic system cancer	0.000344	0.00188	CcSEcCtD
Norfloxacin—Leukopenia—Carmustine—lymphatic system cancer	0.000343	0.00187	CcSEcCtD
Norfloxacin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	0.000342	0.0541	CbGdCrCtD
Norfloxacin—Anorexia—Bleomycin—lymphatic system cancer	0.000341	0.00186	CcSEcCtD
Norfloxacin—Agitation—Vincristine—lymphatic system cancer	0.000336	0.00183	CcSEcCtD
Norfloxacin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000336	0.00183	CcSEcCtD
Norfloxacin—Photosensitivity—Methotrexate—lymphatic system cancer	0.000336	0.00183	CcSEcCtD
Norfloxacin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000334	0.00182	CcSEcCtD
Norfloxacin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	0.000333	0.0526	CbGdCrCtD
Norfloxacin—Convulsion—Carmustine—lymphatic system cancer	0.000332	0.00181	CcSEcCtD
Norfloxacin—Nausea—Teniposide—lymphatic system cancer	0.00033	0.0018	CcSEcCtD
Norfloxacin—Vertigo—Vincristine—lymphatic system cancer	0.000329	0.00179	CcSEcCtD
Norfloxacin—Hepatic failure—Methotrexate—lymphatic system cancer	0.000328	0.00179	CcSEcCtD
Norfloxacin—Leukopenia—Vincristine—lymphatic system cancer	0.000327	0.00178	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000326	0.00178	CcSEcCtD
Norfloxacin—Myalgia—Carmustine—lymphatic system cancer	0.000326	0.00178	CcSEcCtD
Norfloxacin—Chest pain—Carmustine—lymphatic system cancer	0.000326	0.00178	CcSEcCtD
Norfloxacin—Anxiety—Carmustine—lymphatic system cancer	0.000325	0.00177	CcSEcCtD
Norfloxacin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000322	0.00175	CcSEcCtD
Norfloxacin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000319	0.00174	CcSEcCtD
Norfloxacin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000319	0.00174	CcSEcCtD
Norfloxacin—Convulsion—Vincristine—lymphatic system cancer	0.000317	0.00173	CcSEcCtD
Norfloxacin—Confusional state—Carmustine—lymphatic system cancer	0.000315	0.00172	CcSEcCtD
Norfloxacin—Oedema—Carmustine—lymphatic system cancer	0.000313	0.0017	CcSEcCtD
Norfloxacin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000312	0.0017	CcSEcCtD
Norfloxacin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000311	0.0017	CcSEcCtD
Norfloxacin—Myalgia—Vincristine—lymphatic system cancer	0.000311	0.0017	CcSEcCtD
Norfloxacin—Visual disturbance—Methotrexate—lymphatic system cancer	0.000311	0.00169	CcSEcCtD
Norfloxacin—Vomiting—Fludarabine—lymphatic system cancer	0.000311	0.00169	CcSEcCtD
Norfloxacin—Convulsion—Mitoxantrone—lymphatic system cancer	0.000309	0.00168	CcSEcCtD
Norfloxacin—Rash—Fludarabine—lymphatic system cancer	0.000308	0.00168	CcSEcCtD
Norfloxacin—Dermatitis—Fludarabine—lymphatic system cancer	0.000308	0.00168	CcSEcCtD
Norfloxacin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000306	0.00167	CcSEcCtD
Norfloxacin—Headache—Fludarabine—lymphatic system cancer	0.000306	0.00167	CcSEcCtD
Norfloxacin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000304	0.00166	CcSEcCtD
Norfloxacin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000303	0.00165	CcSEcCtD
Norfloxacin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000303	0.00165	CcSEcCtD
Norfloxacin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000303	0.00165	CcSEcCtD
Norfloxacin—Anxiety—Mitoxantrone—lymphatic system cancer	0.000302	0.00165	CcSEcCtD
Norfloxacin—Oedema—Vincristine—lymphatic system cancer	0.000298	0.00162	CcSEcCtD
Norfloxacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000298	0.00162	CcSEcCtD
Norfloxacin—Anorexia—Carmustine—lymphatic system cancer	0.000298	0.00162	CcSEcCtD
Norfloxacin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000295	0.00161	CcSEcCtD
Norfloxacin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000295	0.0016	CcSEcCtD
Norfloxacin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000293	0.0016	CcSEcCtD
Norfloxacin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000292	0.00159	CcSEcCtD
Norfloxacin—Oedema—Mitoxantrone—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Norfloxacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Norfloxacin—Nausea—Fludarabine—lymphatic system cancer	0.00029	0.00158	CcSEcCtD
Norfloxacin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000289	0.00157	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000285	0.00155	CcSEcCtD
Norfloxacin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000285	0.00155	CcSEcCtD
Norfloxacin—Urticaria—Bleomycin—lymphatic system cancer	0.000285	0.00155	CcSEcCtD
Norfloxacin—Anorexia—Vincristine—lymphatic system cancer	0.000284	0.00155	CcSEcCtD
Norfloxacin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000283	0.00154	CcSEcCtD
Norfloxacin—Insomnia—Carmustine—lymphatic system cancer	0.000283	0.00154	CcSEcCtD
Norfloxacin—Irritability—Methotrexate—lymphatic system cancer	0.000281	0.00153	CcSEcCtD
Norfloxacin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000281	0.00153	CcSEcCtD
Norfloxacin—Paraesthesia—Carmustine—lymphatic system cancer	0.000281	0.00153	CcSEcCtD
Norfloxacin—Dyspnoea—Carmustine—lymphatic system cancer	0.000279	0.00152	CcSEcCtD
Norfloxacin—Somnolence—Carmustine—lymphatic system cancer	0.000278	0.00151	CcSEcCtD
Norfloxacin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000277	0.00151	CcSEcCtD
Norfloxacin—Ataxia—Methotrexate—lymphatic system cancer	0.000277	0.00151	CcSEcCtD
Norfloxacin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000272	0.00148	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000272	0.00148	CcSEcCtD
Norfloxacin—Decreased appetite—Carmustine—lymphatic system cancer	0.000272	0.00148	CcSEcCtD
Norfloxacin—Insomnia—Vincristine—lymphatic system cancer	0.00027	0.00147	CcSEcCtD
Norfloxacin—Paraesthesia—Vincristine—lymphatic system cancer	0.000268	0.00146	CcSEcCtD
Norfloxacin—Constipation—Carmustine—lymphatic system cancer	0.000267	0.00146	CcSEcCtD
Norfloxacin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000265	0.00144	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000265	0.00144	CcSEcCtD
Norfloxacin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000264	0.00144	CcSEcCtD
Norfloxacin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000261	0.00142	CcSEcCtD
Norfloxacin—Decreased appetite—Vincristine—lymphatic system cancer	0.000259	0.00141	CcSEcCtD
Norfloxacin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000259	0.00141	CcSEcCtD
Norfloxacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000258	0.00141	CcSEcCtD
Norfloxacin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000258	0.0014	CcSEcCtD
Norfloxacin—Fatigue—Vincristine—lymphatic system cancer	0.000257	0.0014	CcSEcCtD
Norfloxacin—Asthenia—Bleomycin—lymphatic system cancer	0.000257	0.0014	CcSEcCtD
Norfloxacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000256	0.00139	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000256	0.00139	CcSEcCtD
Norfloxacin—Constipation—Vincristine—lymphatic system cancer	0.000255	0.00139	CcSEcCtD
Norfloxacin—Pruritus—Bleomycin—lymphatic system cancer	0.000253	0.00138	CcSEcCtD
Norfloxacin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000253	0.00138	CcSEcCtD
Norfloxacin—Eosinophilia—Methotrexate—lymphatic system cancer	0.000252	0.00137	CcSEcCtD
Norfloxacin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000251	0.00136	CcSEcCtD
Norfloxacin—Pancreatitis—Methotrexate—lymphatic system cancer	0.00025	0.00136	CcSEcCtD
Norfloxacin—Constipation—Mitoxantrone—lymphatic system cancer	0.000249	0.00135	CcSEcCtD
Norfloxacin—Abdominal pain—Carmustine—lymphatic system cancer	0.000247	0.00135	CcSEcCtD
Norfloxacin—Body temperature increased—Carmustine—lymphatic system cancer	0.000247	0.00135	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000244	0.00133	CcSEcCtD
Norfloxacin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00024	0.0013	CcSEcCtD
Norfloxacin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	0.000239	0.0377	CbGdCrCtD
Norfloxacin—Neutropenia—Methotrexate—lymphatic system cancer	0.000238	0.0013	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000238	0.00129	CcSEcCtD
Norfloxacin—Abdominal pain—Vincristine—lymphatic system cancer	0.000236	0.00128	CcSEcCtD
Norfloxacin—Body temperature increased—Vincristine—lymphatic system cancer	0.000236	0.00128	CcSEcCtD
Norfloxacin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000232	0.00127	CcSEcCtD
Norfloxacin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000231	0.00126	CcSEcCtD
Norfloxacin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00023	0.00125	CcSEcCtD
Norfloxacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00023	0.00125	CcSEcCtD
Norfloxacin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00023	0.00125	CcSEcCtD
Norfloxacin—Vomiting—Bleomycin—lymphatic system cancer	0.000228	0.00124	CcSEcCtD
Norfloxacin—Drowsiness—Methotrexate—lymphatic system cancer	0.000227	0.00124	CcSEcCtD
Norfloxacin—Rash—Bleomycin—lymphatic system cancer	0.000226	0.00123	CcSEcCtD
Norfloxacin—Dermatitis—Bleomycin—lymphatic system cancer	0.000226	0.00123	CcSEcCtD
Norfloxacin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	0.000225	0.0356	CbGdCrCtD
Norfloxacin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000225	0.00123	CcSEcCtD
Norfloxacin—Asthenia—Carmustine—lymphatic system cancer	0.000224	0.00122	CcSEcCtD
Norfloxacin—Renal failure—Methotrexate—lymphatic system cancer	0.000223	0.00122	CcSEcCtD
Norfloxacin—Stomatitis—Methotrexate—lymphatic system cancer	0.000221	0.00121	CcSEcCtD
Norfloxacin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000221	0.0012	CcSEcCtD
Norfloxacin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00022	0.0012	CcSEcCtD
Norfloxacin—Haematuria—Methotrexate—lymphatic system cancer	0.000216	0.00118	CcSEcCtD
Norfloxacin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000214	0.00117	CcSEcCtD
Norfloxacin—Asthenia—Vincristine—lymphatic system cancer	0.000214	0.00117	CcSEcCtD
Norfloxacin—Diarrhoea—Carmustine—lymphatic system cancer	0.000214	0.00116	CcSEcCtD
Norfloxacin—Nausea—Bleomycin—lymphatic system cancer	0.000213	0.00116	CcSEcCtD
Norfloxacin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000212	0.00115	CcSEcCtD
Norfloxacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000209	0.00114	CcSEcCtD
Norfloxacin—Dizziness—Carmustine—lymphatic system cancer	0.000207	0.00113	CcSEcCtD
Norfloxacin—Diarrhoea—Vincristine—lymphatic system cancer	0.000204	0.00111	CcSEcCtD
Norfloxacin—Hepatitis—Methotrexate—lymphatic system cancer	0.000204	0.00111	CcSEcCtD
Norfloxacin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000199	0.00108	CcSEcCtD
Norfloxacin—Vomiting—Carmustine—lymphatic system cancer	0.000199	0.00108	CcSEcCtD
Norfloxacin—Dizziness—Vincristine—lymphatic system cancer	0.000197	0.00107	CcSEcCtD
Norfloxacin—Rash—Carmustine—lymphatic system cancer	0.000197	0.00107	CcSEcCtD
Norfloxacin—Dermatitis—Carmustine—lymphatic system cancer	0.000197	0.00107	CcSEcCtD
Norfloxacin—Visual impairment—Methotrexate—lymphatic system cancer	0.000196	0.00107	CcSEcCtD
Norfloxacin—Headache—Carmustine—lymphatic system cancer	0.000196	0.00107	CcSEcCtD
Norfloxacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000193	0.00105	CcSEcCtD
Norfloxacin—Tinnitus—Methotrexate—lymphatic system cancer	0.00019	0.00103	CcSEcCtD
Norfloxacin—Vomiting—Vincristine—lymphatic system cancer	0.00019	0.00103	CcSEcCtD
Norfloxacin—Rash—Vincristine—lymphatic system cancer	0.000188	0.00102	CcSEcCtD
Norfloxacin—Dermatitis—Vincristine—lymphatic system cancer	0.000188	0.00102	CcSEcCtD
Norfloxacin—Headache—Vincristine—lymphatic system cancer	0.000187	0.00102	CcSEcCtD
Norfloxacin—Nausea—Carmustine—lymphatic system cancer	0.000186	0.00101	CcSEcCtD
Norfloxacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000185	0.00101	CcSEcCtD
Norfloxacin—Rash—Mitoxantrone—lymphatic system cancer	0.000183	0.000998	CcSEcCtD
Norfloxacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000183	0.000997	CcSEcCtD
Norfloxacin—Chills—Methotrexate—lymphatic system cancer	0.000183	0.000996	CcSEcCtD
Norfloxacin—Headache—Mitoxantrone—lymphatic system cancer	0.000182	0.000991	CcSEcCtD
Norfloxacin—Erythema—Methotrexate—lymphatic system cancer	0.000177	0.000966	CcSEcCtD
Norfloxacin—Nausea—Vincristine—lymphatic system cancer	0.000177	0.000965	CcSEcCtD
Norfloxacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000174	0.000946	CcSEcCtD
Norfloxacin—Nausea—Mitoxantrone—lymphatic system cancer	0.000173	0.00094	CcSEcCtD
Norfloxacin—Back pain—Methotrexate—lymphatic system cancer	0.000172	0.000934	CcSEcCtD
Norfloxacin—Vision blurred—Methotrexate—lymphatic system cancer	0.000167	0.00091	CcSEcCtD
Norfloxacin—Vertigo—Methotrexate—lymphatic system cancer	0.000159	0.000868	CcSEcCtD
Norfloxacin—Leukopenia—Methotrexate—lymphatic system cancer	0.000159	0.000865	CcSEcCtD
Norfloxacin—Convulsion—Methotrexate—lymphatic system cancer	0.000154	0.000837	CcSEcCtD
Norfloxacin—Myalgia—Methotrexate—lymphatic system cancer	0.000151	0.000822	CcSEcCtD
Norfloxacin—Chest pain—Methotrexate—lymphatic system cancer	0.000151	0.000822	CcSEcCtD
Norfloxacin—Arthralgia—Methotrexate—lymphatic system cancer	0.000151	0.000822	CcSEcCtD
Norfloxacin—Confusional state—Methotrexate—lymphatic system cancer	0.000146	0.000795	CcSEcCtD
Norfloxacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000145	0.000788	CcSEcCtD
Norfloxacin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000142	0.000772	CcSEcCtD
Norfloxacin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00014	0.000762	CcSEcCtD
Norfloxacin—Anorexia—Methotrexate—lymphatic system cancer	0.000138	0.000752	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000132	0.000718	CcSEcCtD
Norfloxacin—Insomnia—Methotrexate—lymphatic system cancer	0.000131	0.000713	CcSEcCtD
Norfloxacin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00013	0.000708	CcSEcCtD
Norfloxacin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000129	0.000703	CcSEcCtD
Norfloxacin—Somnolence—Methotrexate—lymphatic system cancer	0.000129	0.000701	CcSEcCtD
Norfloxacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000127	0.000694	CcSEcCtD
Norfloxacin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000126	0.000685	CcSEcCtD
Norfloxacin—Fatigue—Methotrexate—lymphatic system cancer	0.000125	0.00068	CcSEcCtD
Norfloxacin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000119	0.00065	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000118	0.000645	CcSEcCtD
Norfloxacin—Urticaria—Methotrexate—lymphatic system cancer	0.000115	0.000626	CcSEcCtD
Norfloxacin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000114	0.000623	CcSEcCtD
Norfloxacin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000114	0.000623	CcSEcCtD
Norfloxacin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000107	0.000581	CcSEcCtD
Norfloxacin—Asthenia—Methotrexate—lymphatic system cancer	0.000104	0.000566	CcSEcCtD
Norfloxacin—Pruritus—Methotrexate—lymphatic system cancer	0.000102	0.000558	CcSEcCtD
Norfloxacin—Diarrhoea—Methotrexate—lymphatic system cancer	9.91e-05	0.000539	CcSEcCtD
Norfloxacin—Dizziness—Methotrexate—lymphatic system cancer	9.58e-05	0.000521	CcSEcCtD
Norfloxacin—Vomiting—Methotrexate—lymphatic system cancer	9.21e-05	0.000501	CcSEcCtD
Norfloxacin—Rash—Methotrexate—lymphatic system cancer	9.13e-05	0.000497	CcSEcCtD
Norfloxacin—Dermatitis—Methotrexate—lymphatic system cancer	9.12e-05	0.000497	CcSEcCtD
Norfloxacin—Headache—Methotrexate—lymphatic system cancer	9.07e-05	0.000494	CcSEcCtD
Norfloxacin—Nausea—Methotrexate—lymphatic system cancer	8.6e-05	0.000468	CcSEcCtD
